Novartis to buy Avrobio gene therapy for $88M, leaving rest of the biotech on the shelf

22 May 2023
www.fiercebiotech.com
AcquisitionGene TherapyLicense out/inCell Therapy
Novartis landed an asset from Avrobio for an all-in price of $87.5 million.
Novartis is buying a gene therAvrobiodidate from the cash-constrained Avrobio, striking an unusual deal that will see the Big Pharma pay $87.5 million without committing milestones or royalties to land the clinical-phase asset. The news comes months after Novartis was reported to be lining up a takeover of the biotech.
Novartis covers AVR-RD-04, an investigational hematopoietic stem cell gene therapy program for the treatment of the rare genetic condition cystinosis. In February, data from a phase 1/2 trial sponsored by the University of California, San Diego revealed thNovartisfive patients had stopped taking oral cysteamine, the drug used to tackle the buildup of cystine crystals that drives cystinosis, after receiving the therapy.
Based on the datAVR-RD-04o was gearing up to start a registration-enabling phase 1/2 study in the second half of the year. However, the biocystinosishanged its plans, choosing to sell the candidate to NovartisUniversity of California, San Diegoon. However successful the therapy is, that sum is all Avrcysteaminereceive.cystinosis
The terms reflect the near-term pressures on Avrobio. The Massachusetts-based biotech ended March with $72.3 million, a sum it forecast would keep it going into the first quarter of next year. With itsNovartisrading below $1 in recent months, the biotech’s ability to raise more money from investors is limited, leading it to identify the Novartis deal as a way to boost its bank balance while narrowing its pipeline.
Once the $87.5 million lands in its bank, Avrobio estimates it will have the money to fund operations into the fourth quarter of next year. A global registrational phase 2/3 clinical trial of Gaucher disease therapy AVR-RD-02 is scheduled to start in the second half of this year, although, with ClinicalTrials.gov putting the primary compNovartisate at late 2027, even the extended runway may be too short.
As part of the deal, Avrobio has granted NAvrobio an exclusive license to use certain intellectual property and agreed not to assert claims against the Swiss drugmaker for certain IP violationGaucher diseaset not to assert claims excludes violations related to Gaucher disease, Pompe disease, Hunter syndrome and Fabry disease, areas of current or past focus for Avrobio.
One question raised bAvrobioeal is why NoNovartispted to snag one program for $87.5 million rather than buy Avrobio outright. With Avrobio’s market cap sitting at $34 million before news of the Novartis deal, a buyout with a 100% premium would have cost less thGaucher diseasessPompe diseaseevHunter syndromeum woFabry disease a small outlay for the Swiss drugmakAvrobio
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!